Navigation Links
Biovail Concerned Shareholders Welcome Glass Lewis Evaluation

Independent Report Sharply Criticizes Current Management

Recommends 'Do Not Vote' For Any of the Company's Nominees

TORONTO, June 18 /PRNewswire/ -- The Concerned Shareholders of Biovail Corporation (NYSE: BVF)(TSX: BVF) said today that they welcomed a report by Glass Lewis & Co., which sharply criticized the incumbent board and recommended 'Do Not Vote' for any of the company's nominees.

Glass Lewis recommended a vote FOR two of the Concerned Shareholders nominees, Joseph J. Krivulka and Laurence W. Zeifman. It recommended withholding votes from the other eight nominees on the Concerned Shareholders' slate.

The Glass Lewis report took issue with several actions by the current board, particularly its executive appointments and compensation packages.

"While the board should be seeking to put its troubled history in the past, it has instead appointed its former CEO as chairman and a former member of an audit committee which oversaw significant restatements as its new CEO," the report says. "We believe that shareholders could benefit from the addition of new independent voices on the board with appropriate subject matter and industry expertise."

The Glass Lewis report called the appointment of Biovail's CEO, William Wells, "a curious choice at best," as well as "inappropriate from a corporate governance perspective." It concludes: "At the very least such an appointment could only further serve to damage the Company's already bruised public image."

Glass Lewis also expressed disapproval of executive compensation arrangements made by the incumbent board. It notes that Mr. Wells chaired the compensation and nominating committees, and that the retiring CEO, Douglas Squires, was awarded a package of $3.5 million, including a retroactive raise, even though the company's share price was falling.

"An outside observer would conclude that these potentially excessive compensation awards for Messrs. Squires and Wells, especially at a time of poor financial performance, may be related to the appointment of Mr. Wells," the report says. "Even if Mr. Wells' past position in overseeing the committee which determines executive pay and identified the new CEO did not affect his appointment as CEO or the generous contracts for him and his predecessor, the mere appearance of corruption could be damaging."

Bruce D. Brydon, CEO of Biovail during some of its most successful years, who will return as CEO if the Concerned Shareholders' slate is elected, said he wants to get the company back on the right track. Mr. Brydon said: "We believe that Biovail needs a complete change in its board, senior management and direction to avoid even further declines in shareholder value."

Mr. Brydon noted that:

-- In the last year the price of Biovail stock has declined nearly 50%, far worse than the drug industry stock price index.

-- In the last four years, under current management, Biovail has obtained regulatory approval for only one new drug, in sharp contrast to the 17 new drugs that were approved during Mr. Brydon's tenure as CEO from 1995 to 2001.

-- A leading financial analyst who covers Biovail and other drug companies has stated that the new strategic direction announced recently by Biovail's current management, to focus intensive research and development on new chemical entities to treat central nervous system conditions such as Alzheimer's Disease, "is just baffling to us."

All shareholders are urged to vote the YELLOW proxy in favour of the Concerned Shareholders slate of nominees. Copies of the proxy circular prepared by the Concerned Shareholders can be obtained via SEDAR ( and or by contacting in Canada, Kingsdale Shareholder Services Inc. toll-free at 1-800-775-1986 or collect at 1-416-867-2272, or in the United States, Innisfree M&A Incorporated toll-free at 1-877-717-3929.

Certain statements contained in this release constitute forward-looking statements. The words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Concerned Shareholders, the Concerned Shareholders' nominees, the Company or its current or future management, are intended to identify forward-looking statements. Such statements reflect the Concerned Shareholders' or the Concerned Shareholders' nominees' current views with respect to future events and are subject to certain risks, uncertainties and assumptions. The Concerned Shareholders' nominees assume no responsibility for any such statements. Many factors could cause the company's actual results, performance or achievements that may be expressed or implied by such forward- looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include, but are not limited to, economic, business, technological, competitive and regulatory factors.

SOURCE Bruce Brydon
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
2. Biovail Concerned Shareholders Want Open Debate
3. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
6. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
7. Pharmos Issues Letter to Shareholders
8. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
10. YM Biosciences announces adoption of renewed Shareholders Rights Plan
11. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
Post Your Comments:
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... The Academy ... Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the ... last few years. Many AMA members have embraced this type of racing and several ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
Breaking Biology Technology:
(Date:11/17/2015)... PARIS , November 17, 2015 ... November 2015.   --> Paris from ... --> DERMALOG, the biometrics innovation leader, has invented the ... and fingerprints on the same scanning surface. Until now two ... fingerprints. Now one scanner can capture both on the same ...
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
Breaking Biology News(10 mins):